Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06183489
Title Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (ERASMM)
Acronym ERASMM
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Myeloma Network
Age Groups: senior | adult
Covered Countries NLD | ITA | FRA

No variant requirements are available.